Close
Help




JOURNAL

Clinical Medicine Insights: Cardiology

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform

Submit a Paper


Clinical Medicine Insights: Cardiology 2013:7 115-126

Review

Published on 23 Jul 2013

DOI: 10.4137/CMC.S11516


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Cardiology

Abstract

Everolimus-eluting stents (EES) represent the next generation of drug-eluting stents (DES). Important design modifications include thin strut stent backbones, less inflammatory and more biocompatible polymers, and lower drug dosing. The cobalt chromium EES fluoropolymer XIENCE V stent has been the most extensively studied of such stents. In animal models, this stent demonstrated minimal vessel inflammation, a biologically active endothelium with strut coverage similar to a bare metal stent, and inhibition of intimal hyperplasia comparable to that seen with sirolimus-eluting stents. The SPIRIT family of clinical trials demonstrated low rates of late loss, and clinical restenosis, as well as low rates of very late stent thrombosis. These excellent clinical outcomes addressed limitations of the 1st generation DES, and substantiated widespread clinical use of the EES platform.



Downloads

PDF  (1.68 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML




What Your Colleagues Say About Clinical Medicine Insights: Cardiology
My co-authors and I had a very positive experience with the review and publication process in Clinical Medicine Insights: Cardiology.  The review was on point, and publication was also rapid and allowed us the needed revisions in the proof preparation process.
Professor Roberto Pedrinelli (Universita di Pisa, Pisa, Italy)
More Testimonials

Quick Links


New article and journal news notification services